Exosomal lncRNA PCAT-1 promotes Kras-associated chemoresistance via immunosuppressive miR-182/miR-217 signaling and p27/CDK6 regulation.
Kras
PCAT-1
immunosuppression
miR-182
miR-217
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
21 Jul 2020
21 Jul 2020
Historique:
received:
21
12
2019
accepted:
20
06
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
6
8
2020
Statut:
epublish
Résumé
Immunosuppressive chemoresistance is a major burden in lung cancer. Recent data reveal that long noncoding RNAs (lncRNAs) present in the lung tumor microenvironment are implicated in chemoresistant-related immune deregulation, and metastasis but their exact pathogenic role is still unknown. In this study, we investigate the role of lncRNA PCAT-1 in chemoresistant immunosuppression and its involvement in tumor stroma remodeling. Findings reveal PCAT-1 to regulate Kras-related lung chemoresistance through increased expression of the immunosuppressive micrornas miR-182/miR217 in lung tissues, thus promoting a pre-metastatic niche formation and a subsequent increase in lung metastatic burden. Elevated expression of PCAT-1 negative regulates p27/CDK6 expression by inducing G
Identifiants
pubmed: 32754302
doi: 10.18632/oncotarget.27675
pii: 27675
pmc: PMC7381096
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2847-2862Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare no conflicts of interest.
Références
Oncotarget. 2017 Aug 14;8(42):73296-73311
pubmed: 29069870
Biomed Pharmacother. 2019 Feb;110:493-499
pubmed: 30530229
Nat Cell Biol. 2019 Apr;21(4):498-510
pubmed: 30936474
J Exp Clin Cancer Res. 2019 Apr 15;38(1):162
pubmed: 30987642
Front Oncol. 2019 May 03;9:356
pubmed: 31131261
Cancer Res. 2017 Aug 1;77(15):3965-3981
pubmed: 28701486
Immunol Res. 2015 Mar;61(3):338-47
pubmed: 25608795
Mol Cancer. 2017 Aug 29;16(1):148
pubmed: 28851377
Oncotarget. 2017 Feb 14;8(7):12472-12483
pubmed: 27992370
Sci Rep. 2017 Oct 30;7(1):14300
pubmed: 29085026
Cancer Cell. 2016 Apr 11;29(4):452-463
pubmed: 27070700
Mol Cancer. 2019 Mar 30;18(1):67
pubmed: 30927930
Nat Rev Immunol. 2014 Mar;14(3):195-208
pubmed: 24566916
Nat Rev Cancer. 2017 Apr;17(4):209-222
pubmed: 28233802
Theranostics. 2018 Jun 8;8(13):3654-3675
pubmed: 30026873
Nature. 2014 Jan 16;505(7483):344-52
pubmed: 24429633
N Engl J Med. 2017 Aug 31;377(9):849-861
pubmed: 28854088
Oncotarget. 2016 Sep 20;7(38):61741-61754
pubmed: 27557514
Oncogene. 2018 Jul;37(28):3822-3838
pubmed: 29643475
Nat Rev Drug Discov. 2019 Feb;18(2):99-115
pubmed: 30470818
Oncotarget. 2016 Jan 19;7(3):3111-27
pubmed: 26683522
Cancer Res. 2017 Aug 1;77(15):4158-4170
pubmed: 28611041
Nat Rev Clin Oncol. 2018 Oct;15(10):617-638
pubmed: 29795272
Nat Commun. 2018 Jan 8;9(1):94
pubmed: 29311544
Mol Cancer. 2017 Feb 17;16(1):42
pubmed: 28212646
Nat Rev Immunol. 2015 Nov;15(11):669-82
pubmed: 26471778
J Clin Invest. 2017 Mar 1;127(3):761-771
pubmed: 28248199
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Mol Cancer. 2018 Apr 20;17(1):82
pubmed: 29678180
Cancer Lett. 2018 Feb 1;414:107-115
pubmed: 29107112
Science. 2016 Jun 17;352(6292):1417-20
pubmed: 27313039
Biomed Pharmacother. 2020 Feb;122:109461
pubmed: 31918262
Oncogene. 2017 Oct 12;36(41):5661-5667
pubmed: 28604750
Nanoscale. 2020 Apr 3;12(13):7051-7062
pubmed: 32186564
Crit Rev Oncol Hematol. 2016 Dec;108:86-96
pubmed: 27931844
Oncogene. 2019 Jun;38(25):4887-4901
pubmed: 30816343
Semin Cancer Biol. 2018 Dec;53:265-281
pubmed: 30317036
Oncogene. 2020 Jan;39(5):953-974
pubmed: 31601996
Int J Cancer. 2016 Jul 15;139(2):269-80
pubmed: 26875870
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Sci Transl Med. 2017 Jun 21;9(395):
pubmed: 28637928
Nat Med. 2015 Nov;21(11):1253-61
pubmed: 26540387
Nat Immunol. 2018 Oct;19(10):1112-1125
pubmed: 30224822
J Natl Cancer Inst. 2017 Oct 1;109(10):
pubmed: 28383653
Mol Cancer. 2017 Jul 24;16(1):130
pubmed: 28738810
Mol Cancer. 2019 Sep 6;18(1):135
pubmed: 31492160
Mol Immunol. 2020 Feb;118:99-109
pubmed: 31862674
Cell. 2018 Jan 25;172(3):393-407
pubmed: 29373828
Cancer Cell. 2016 May 9;29(5):653-668
pubmed: 27117758
Cancer Res. 2016 Jun 1;76(11):3156-65
pubmed: 27197152
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
EBioMedicine. 2019 Mar;41:200-213
pubmed: 30796006
Oncogene. 2015 Nov 26;34(48):5857-68
pubmed: 25867073
Nature. 2018 Jan 4;553(7686):91-95
pubmed: 29160310
Blood. 2017 Nov 2;130(18):1965-1975
pubmed: 28928124
Carcinogenesis. 2018 Mar 8;39(3):397-406
pubmed: 29346528
Oncotarget. 2016 Sep 27;7(39):64148-64167
pubmed: 27580177